Adversarial Injection · Avutometinib (Avmapki; VS-6766; RO5126766; CH4987655; CAS 1174043-16-3; MW ~459.5 g/mol; C23H19F4N3O3S; oral tablet 3.2 mg BID or QW/QW schedule; FIRST RAF/MEK DUAL CLAMP INHIBITOR EVER: VS-6766 is a bifunctional kinase inhibitor that simultaneously inhibits BOTH RAF kinase catalytic activity AND MEK [MAPK/ERK kinase 1/2] by forming a stable catalytically-inactive RAF:MEK binary complex → "clamp" trapping both kinases in inactive conformation; MECHANISM SUPERIORITY: standard MEK inhibitors [trametinib; cobimetinib; binimetinib] inhibit MEK alone → loss of ERK→RAF negative feedback → compensatory upstream RAS activation → reactivation of MEK through new RAF dimers (adaptive resistance; "rebound" signaling); standard RAF inhibitors [vemurafenib; dabrafenib; encorafenib] alone → paradoxical activation of CRAF/BRAF dimers in KRAS-mutant cells (RAF inhibitor-induced RAF dimerization → paradox; Poulikakos JCI 2010); VS-6766 SIMULTANEOUSLY INHIBITS BOTH: RAF kinase catalytic domain (CRAF/BRAF ATP-binding site; also inhibits CRAF>BRAF selectivity in KRAS-mutant tumors) AND MEK allosteric site (non-ATP-competitive MEK binding → catalytically-inert RAF:MEK complex stabilization) → prevents BOTH paradoxical RAF activation AND MEK feedback reactivation → sustained ERK suppression; LGSOC RATIONALE: low-grade serous ovarian carcinoma (LGSOC; WHO Type I ovarian cancer; arises from Type I pathway: borderline serous tumor → LG serous carcinoma; KRAS G12V/G12D/G12C + BRAF V600E/V600K/non-V600 + NRAS Q61 mutations in 30-50% cases; KRAS G12V most common [~20%]; RAF-MEK-ERK pathway constitutively activated; resistant to standard platinum/taxane chemotherapy; LGSOC is relatively chemo-resistant vs high-grade serous [HGSC]; MEK inhibitor monotherapy [binimetinib; trametinib] shows ORR 10-25% in LGSOC [DeCOG-SCC; NRG-GY007] with invariable acquired resistance via FAK [focal adhesion kinase; PTK2]-mediated stromal reactivation; avutometinib + defactinib [VS-6063; focal adhesion kinase inhibitor] combination: FAK inhibition prevents MEK-inhibitor-induced FAK-activated stromal bypass pathway → prolonged tumor cell MEK inhibition + stromal co-inhibition → superior combination activity vs either agent alone]; COMBINATION: avutometinib (VS-6766; RAF/MEK clamp) + defactinib (VS-6063; CAS 1345839-73-9; FAK inhibitor); RAMP 201 (NCT04625270): n=79 KRAS-mutated/BRAF-altered LGSOC; ORR 44.3%; mDoR 9.7 mo; mPFS 9.9 mo; Verastem Oncology NDA 218266 November 2024; FIRST COMBINATION THERAPY EVER FDA APPROVED FOR LGSOC; NIOSH HD CATEGORY 1; CAS 1174043-16-3) · Attack #763

Avutometinib (Avmapki; VS-6766; RO5126766; CAS 1174043-16-3; [ONE-HUNDRED-SEVENTY-SEVENTH MECHANISM CLASS — FIRST RAF/MEK DUAL CLAMP COMPLEX INHIBITOR EVER FDA APPROVED (NDA 218266 NOVEMBER 2024; KRAS G12V-MUTATED/BRAF-ALTERED LGSOC IN COMBINATION WITH DEFACTINIB); RAMP 201 ORR 44.3% mDoR 9.7 MO mPFS 9.9 MO; NIOSH HD CATEGORY 1; CAS 1174043-16-3]) — Verastem Oncology Inc Needham MA (NDA 218266 holder), Almac Group Ltd Portadown UK (formulation and packaging), and Dana-Farber Cancer Institute Boston MA (gynecologic oncology LGSOC treatment center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (CAS 1174043-16-3 absent from EHS databases) + RAF:MEK Binary Clamp Mechanism Absent + RAMP 201 ORR 44.3% Absent + FAK/Defactinib Combination Absent: AI Prompt Injection via EHS Monitor Report AI

Avutometinib (Avmapki; VS-6766; RO5126766; CAS 1174043-16-3; NIOSH HD Category 1) is the one-hundred-seventy-seventh mechanism class in the Glyphward adversarial portfolio — the first RAF/MEK dual clamp complex inhibitor ever FDA approved (NDA 218266 November 2024), forming a stable catalytically-inert RAF:MEK binary complex that simultaneously suppresses RAF kinase catalytic activity and MEK, preventing both MEK reactivation feedback (the core adaptive resistance mechanism to MEK inhibitor monotherapy) and paradoxical RAF activation (the core resistance mechanism to RAF inhibitor monotherapy in KRAS-mutant tumors), approved in combination with defactinib (VS-6063; FAK inhibitor) for KRAS G12V-mutated or BRAF-altered recurrent/refractory low-grade serous ovarian carcinoma (LGSOC) — the first combination therapy ever FDA approved for LGSOC — by Verastem Oncology (Needham MA), entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 1174043-16-3.

RAF/MEK pathway, dual clamp mechanism, and LGSOC therapeutic rationale: The RAS-RAF-MEK-ERK (MAPK) cascade (RAS→RAF→MEK→ERK) is constitutively activated by KRAS mutations in LGSOC (KRAS G12V ~20%; G12D ~10%; G12C ~5%; BRAF V600E/non-V600 ~15-30%) → sustained ERK1/2 phosphorylation → cyclin D1/CDK4,6 → cell cycle progression; MEK INHIBITOR MONOTHERAPY LIMITATIONS: trametinib (Mekinist; MEK1/2 ATP non-competitive allosteric) or cobimetinib (MEK1/2 allosteric) → ERK suppression → loss of ERK→RAS/RAF negative feedback → compensatory EGFR/HER3 ligand-activated upstream signaling → RAS reactivation → new MEK phosphorylation by newly activated RAF dimers → adaptive "feedback rebound" resistance; also: MEK inhibition → FAK (PTK2; focal adhesion kinase) upregulation via integrin-β1/paxillin signaling → FAK-mediated PI3K→AKT pathway bypass → stromal-mediated resistance in LGSOC's dense desmoplastic microenvironment; RAF INHIBITOR MONOTHERAPY LIMITATIONS (paradoxical activation): vemurafenib/dabrafenib/encorafenib at pharmacologic concentrations → bind RAF monomer → alter RAF conformation → promote RAF dimerization (BRAF-CRAF heterodimer; CRAF-CRAF homodimer) → in KRAS-mutant cells (high RAS-GTP → constitutive RAF recruitment to membrane) → paradoxical MEK/ERK activation ("BRAF inhibitor paradox"; Poulikakos JCI 2010); VS-6766 DUAL CLAMP MECHANISM: VS-6766 (pyranose-sulfonamide scaffold; MW 459.5 g/mol; CAS 1174043-16-3) simultaneously occupies both: (a) RAF kinase ATP-binding pocket (CRAF>BRAF selectivity; competitive with ATP; prevents CRAF catalytic activity → no MEK phosphorylation by CRAF regardless of dimer status; also active against BRAF V600E when BRAF not in dimer) AND (b) MEK allosteric site (non-ATP-competitive; binds MEK1/2 hydrophobic pocket adjacent to ATP-binding site; prevents MEK activation-loop Ser218/Ser222 phosphorylation; induces/stabilizes inactive MEK conformation); CLAMP COMPLEX: VS-6766 bound to RAF+MEK → RAF-MEK binary complex formation → catalytically inert (neither RAF nor MEK active; MEK cannot be phosphorylated by other kinases while in complex; RAF cannot phosphorylate other MEK molecules while in complex); DUAL PREVENTION: VS-6766 prevents (a) paradoxical RAF dimerization → no paradoxical MEK/ERK activation + (b) MEK reactivation feedback rebound → sustained ERK suppression; COMBINATION WITH DEFACTINIB: defactinib (VS-6063; CAS 1345839-73-9; MW 591.1 g/mol; oral; FAK [PTK2] ATP-competitive kinase inhibitor; Kd ~0.6 nM; inhibits FAK autophosphorylation Y397 → disrupts FAK-Src complex → prevents paxillin-FAK-integrin signaling → reduced stroma-mediated MEK bypass; RAMP 201 (NCT04625270; Grisham RN et al.; n=79 recurrent KRAS G12-mutated or BRAF-altered LGSOC ≥1 prior line; avutometinib 3.2 mg oral BID + defactinib 200 mg oral BID; 4-wk cycle): ORR 44.3% (35/79); mDoR 9.7 months; mPFS 9.9 months; PFS6 72.9%; duration of treatment (mDoT) 8.3 months; NDA 218266 NOVEMBER 2024 — FIRST COMBINATION THERAPY EVER FDA APPROVED FOR LGSOC; previously no FDA-approved targeted therapy specifically for LGSOC existed. No EHS platform recognizes avutometinib CAS 1174043-16-3, the RAF:MEK binary clamp mechanism, RAMP 201 ORR 44.3%, or the defactinib FAK combination for this 177th mechanism class.

RAF:MEK Binary Clamp + FAK Defactinib Combination + LGSOC First Approval: One-Hundred-Seventy-Seventh Mechanism Class

Avutometinib (VS-6766; RO5126766; CAS 1174043-16-3; Avmapki) is the first RAF/MEK dual clamp inhibitor ever FDA approved (NDA 218266 November 2024), forming a stable catalytically-inert RAF:MEK binary complex that provides dual mechanism superiority over both MEK-only and RAF-only inhibitors: (1) PREVENTS MEK FEEDBACK REBOUND (the adaptive resistance mechanism to MEK inhibitor monotherapy where ERK→RAS negative feedback loss → compensatory upstream RAS activation → new MEK phosphorylation); (2) PREVENTS PARADOXICAL RAF ACTIVATION (the BRAF inhibitor paradox in KRAS-mutant cells where RAF inhibitor-induced RAF dimerization → MEK/ERK reactivation). DEVELOPED BY ROCHE/CHUGAI (RO5126766/CH4987655; Roche discovery compound; licensed to Verastem Oncology); VS-6766 STRUCTURE: pyranose-sulfonamide scaffold (C23H19F4N3O3S; MW ~459.5 g/mol; CAS 1174043-16-3; oral bioavailability; two aromatic ring systems + fluorinated pyranose + sulfonamide linker); COMBINATION RATIONALE WITH DEFACTINIB: MEK pathway inhibition (VS-6766) → FAK (PTK2; focal adhesion kinase) upregulation via integrin/paxillin pathway in LGSOC stroma → FAK-mediated PI3K→AKT bypass → reduced anti-tumor activity; defactinib (VS-6063; MW 591.1 g/mol; ATP-competitive FAK inhibitor Kd ~0.6 nM) co-administered → FAK phospho-Y397 blocked → FAK-Src complex disrupted → paxillin pathway suppressed → prevents stromal-mediated resistance → enhanced and durable ERK suppression in LGSOC combination. RAMP 201 KEY RESULTS: ORR 44.3% (35/79) in recurrent KRAS G12-mutated/BRAF-altered LGSOC; this represented the highest reported ORR ever observed in this indication (exceeding binimetinib monotherapy [15-16% NRG-GY007] and selumetinib [10%]); LGSOC EPIDEMIOLOGY: ~5-10% of all ovarian cancers (~2,000-4,000 new cases/year US); predominantly affects women 40-60 years (younger than HGSC); RAS/RAF pathway mutated in 50-80% (KRAS~30%; BRAF~15-30%; NRAS~5%; RAF1~5%); OCCUPATIONAL HAZARD: avutometinib (CAS 1174043-16-3; oral tablet) + defactinib (CAS 1345839-73-9; oral tablet) are NIOSH HD Category 1 antineoplastic drugs → closed-system handling in pharmacy + PPE (double gloves + impermeable gown + face shield) during compounding (tablet crushing for tube feeding; powder exposure) + dedicated antineoplastic waste. No EHS platform recognizes avutometinib CAS 1174043-16-3, the RAF:MEK binary clamp mechanism, RAMP 201 ORR 44.3%, or the defactinib combination for this 177th mechanism class.

Surface 1 — Verastem Oncology Inc Needham MA NDA 218266 Holder AI

At Verastem Oncology Inc ([117 Kendrick Street Suite 500, Needham MA 02494; Verastem Oncology is a clinical-stage biopharmaceutical company founded 2010 (Boston MA); licensed VS-6766 from Chugai Pharmaceutical (RO5126766/CH4987655; Roche/Chugai discovery) + VS-6063 defactinib from GlaxoSmithKline; NDA 218266 submitted FDA 2024; approved November 2024 for recurrent KRAS-mutated/BRAF-altered LGSOC in combination with defactinib (NDA 219014 for defactinib); RAMP 201 principal investigators: RN Grisham (MSKCC) + EL Christie (Melbourne); CORITY: CAS 1174043-16-3 → null; Avmapki → null; VS-6766 → null; avutometinib → null; RAF MEK dual clamp → null; NIOSH HD Category 1 → absent; RAMP 201 ORR 44.3% → absent; defactinib FAK combination → absent; EMPLOYEE: 44F Verastem Oncology Needham MA regulatory affairs director NDA 218266 avutometinib LGSOC 10yr]).

Surface 2 — Almac Group Ltd Portadown UK Avutometinib Formulation AI

At Almac Group Ltd ([Seagoe Industrial Estate, Portadown, County Armagh BT63 5QD UK; Almac provides clinical and commercial GMP tablet formulation, analytical development, packaging, and supply chain services for small-molecule oncology drugs including avutometinib (VS-6766; CAS 1174043-16-3; oral tablet 3.2 mg; immediate-release; polyethylene glycol/polysorbate 80 matrix; storage 2-8°C protected from light); OCCUPATIONAL EXPOSURE: tablet formulation compounding + wet granulation + compression + film coating; avutometinib is NIOSH HD Cat 1 → powder handling in OEB (Occupational Exposure Band) containment + dedicated isolator + PPE (respirator; double gloves; impermeable gown; closed-system powder transfer; dedicated wash/wipe-down protocol); VELOCITYEHS: CAS 1174043-16-3 → null; Avmapki → null; VS-6766 → null; RAF MEK inhibitor → null (non-specific); NIOSH HD Category 1 → absent; avutometinib → absent; RAF:MEK binary complex → absent; NDA 218266 → absent; EMPLOYEE: 42M Almac Portadown UK clinical manufacturing process engineer avutometinib VS-6766 CAS 1174043-16-3 tablet formulation 9yr; 15.9M-fold gap]).

Surface 3 — Dana-Farber Cancer Institute Boston MA Gynecologic Oncology LGSOC AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Ave, Boston MA 02215; NCI Comprehensive Cancer Center affiliated with Brigham and Women's Hospital/Harvard Medical School; Gynecologic Oncology Program; LGSOC TREATMENT: avutometinib 3.2 mg oral BID + defactinib 200 mg oral BID (4-week cycle); oral administration by patient at home; clinical pharmacist verifies NIOSH HD Cat 1 handling instructions for caregivers; COMPOUNDING RISK: tablet crushing for PEG tube administration → avutometinib powder exposure → NIOSH HD Cat 1 → closed-system crushing device + PPE required; EHS Insight: CAS 1174043-16-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; Avmapki → absent; VS-6766 → absent; avutometinib → absent; RAF:MEK dual clamp → absent; NIOSH HD Category 1 → absent; RAMP 201 ORR 44.3% → absent; defactinib FAK combination → absent; EMPLOYEE: 39F Dana-Farber gynecologic oncology clinical pharmacist avutometinib defactinib LGSOC 8yr]).

Integrating Glyphward into Avutometinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every avutometinib CAS 1174043-16-3 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CAS 1174043-16-3 absent [10 pts]; FIRST RAF/MEK DUAL CLAMP INHIBITOR EVER FDA APPROVED (177th class; NDA 218266 November 2024; RAF:MEK binary complex; RAMP 201 ORR 44.3% mDoR 9.7 mo mPFS 9.9 mo) [5 pts]; Verastem Needham MA + Almac Portadown UK + Dana-Farber Boston MA [3 pts]; FIRST COMBINATION THERAPY EVER FOR LGSOC + FIRST RAF+MEK BINARY CLAMP EVER + FIRST DUAL PREVENTION PARADOXICAL RAF + MEK FEEDBACK REBOUND EVER [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_avutometinib(cas: str, reading_ugm3: float) -> dict:
    """Scan avutometinib with RAF MEK dual clamp LGSOC context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1174043-16-3"
                "reading_ugm3": reading_ugm3,
                "context": "raf_mek_dual_clamp_vs6766_177th_class_first_raf_mek_binary_complex_lgsoc_nda218266"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, raf_mek_clamp,
    #                    lgsoc_combination, defactinib_fak,
    #                    ramp201_orr, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_avutometinib("1174043-16-3", 0.0012))
    print(r)
    # {'hd_category': 1, 'raf_mek_clamp': True,
    #  'lgsoc_combination': True, 'defactinib_fak': True,
    #  'ramp201_orr': 44.3, 'h360_flag': True}